Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co appoints new financial head

Baxter’s Robert Davis takes over from Peter Kellogg
Robert Davis Merck

Merck & Co's long-time chief financial officer Peter Kellogg is to step down within the next two months and will be replaced by Baxter's Robert Davis.

Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

To help with the transition, Kellogg will work closely with Davis (pictured) when he joins on April 23, staying with Merck until May 16.

Davis, who currently serves as VP and president of Baxter's medical products business – a role he has held since 2010, also has great industry experience.

He first joined Baxter in 2004 as chief financial officer of the company's renal business and prior to this spent 14 years at Lilly.

Commenting on the departure of Kellogg, Merck's CEO Kenneth Frazier said: "Peter has been an important member of the Merck leadership team and instrumental in helping to guide Merck during a period of significant change at our company and in our industry.”

31st March 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics